Akebia Therapeutics, Inc. AKBA

Latest FY: 2025 Healthcare Drug Manufacturers - Specialty & Generic
Market Price $0.98
Market Cap $262.89M
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑47.5% YoY
$236.20M
3-Yr CAGR: -6.9%
Net Income ↑92.3% YoY
-$5.34M
Net Margin: -2.3%
Free Cash Flow ↑266.4% YoY
$67.70M
FCF Yield: 25.75%
EPS (Diluted) ↑93.9% YoY
$-0.02
Basic: $-0.02
Return on Equity Efficiency
-16.4%
ROA: -1.4%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (AKBA)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $1.5M $-114.2M $-135.7M 0.00% $57.9M $55.2M
FY 2017 $181.2M +11,706.3% $-49.7M $-73.7M +45.7% $-1.77 0.00% $-56.2M $-57.8M -204.6%
FY 2018 $207.7M +14.6% $201.5M $-143.6M -94.9% $-2.47 -39.5% 0.00% $-97.5M $-99.1M -71.5%
FY 2019 $335.0M +61.3% $189.7M $-279.7M -94.8% $-2.36 +4.5% 0.00% $-257.4M $-264.1M -166.5%
FY 2020 $295.3M -11.8% $-0.6M $-383.5M -37.1% $-2.77 -17.4% 0.00% $-110.4M $-110.7M +58.1%
FY 2021 $213.6M -27.7% $60.2M $-282.8M +26.2% $-1.70 +38.6% 0.00% $-253.0M $-253.0M -128.6%
FY 2022 $292.5M +36.9% $206.9M $-94.2M +66.7% $-0.52 +69.4% 0.00% $-73.2M $-73.3M +71.0%
FY 2023 $194.6M -33.5% $120.5M $-51.9M +44.9% $-0.28 +46.2% 0.00% $-23.4M $-23.4M +68.1%
FY 2024 $160.2M -17.7% $97.0M $-69.4M -33.7% $-0.33 -17.9% 0.00% $-40.7M $-40.7M -74.0%
FY 2025 $236.2M +47.5% $196.7M $-5.3M +92.3% $-0.02 +93.9% 0.00% $68.0M $67.7M +266.4%
$

Valuation

Market Price $0.98
Market Cap $262.89M
Enterprise Value $126.30M
P/E Ratio N/A
P/B Ratio 8.07
FCF Yield 25.75%
Dividend Yield N/A
Shares Outstanding 268,258,200
%

Profitability & Margins

Gross Margin 83.29%
Operating Margin 9.95%
Net Margin -2.26%
Return on Equity (ROE) -16.39%
Return on Assets (ROA) -1.42%
Asset Turnover 0.63x
Revenue 3-Yr CAGR -6.88%
🛡️

Financial Health & Liquidity

Current Ratio 1.55
Cash Ratio 1.13
Debt / Equity 1.480
Debt / Assets 0.128
Cash & Equivalents $184.84M
Total Debt $48.25M
Book Value / Share $0.12
💧

Cash Flow Efficiency

Operating Cash Flow $67.99M
Capital Expenditures (CapEx) $291.00K
Free Cash Flow $67.70M
OCF / Revenue 28.79%
FCF / Revenue 28.66%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $-0.02
EPS (Basic) $-0.02
Dividends / Share N/A
Book Value / Share $0.12
EPS YoY Growth 93.94%
🏛️

Balance Sheet (FY 2025)

Total Assets $376.56M
Total Liabilities $343.95M
Stockholders' Equity $32.61M
Current Assets $252.96M
Current Liabilities $162.94M